OGN (Organon) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 04, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Organon Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Organon's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Organon's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Organon's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organon's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Organon's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Organon (NYSE:OGN) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Organon Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Organon's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

OGN:Mexico 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Executives

Kirke Weaver	officer: Gen. Counsel & Corp. Secy.	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco	director	ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman	officer: General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco	officer: Corporate Controller	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler	officer: Chief Commercial Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita	officer: Head of Global Business Svcs	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr.	officer: Head of Manufacturing	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione	officer: Chief Human Resources Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah	director	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter	officer: Hd of Ext. Affairs and ESG	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan	officer: Head of Research & Development	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139